Presentation is loading. Please wait.

Presentation is loading. Please wait.

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Published bySolomon Hubbard Modified over 6 years ago

Similar presentations

Presentation on theme: "Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects."— Presentation transcript:

1 Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region.
From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8): doi: /382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

2 Table 3. Diversity of hepatitis C virus (HCV) quasi species, by HCV response group.
From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8): doi: /382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

3 Table 4. Correlation between change in hepatitis C virus (HCV) load and change in quasi species parameters. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8): doi: /382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

4 Table 5. Correlation between change in CD4 cell count and change in quasi species parameters.
From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8): doi: /382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

5 Table 1. Baseline demographic and virologic characteristics of HIV-hepatitis C virus (HCV)-coinfected subjects, by HCV response group. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8): doi: /382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

6 Figure 2. Minimum evolution tree for envelope glycoprotein 1 (E1) consensus sequences. Relevant bootstrap values >70 (of 100) are shown. Reference sequences include hepatitis C virus (HCV) genotype 1a (black circles), HCV genotype 1b (white circles), HCV genotype 1c (gray circle), and HCV non-1 genotypes (white squares). Patients in the HCV increaser or HCV stable group are labeled “INC” or “S”, respectively, followed by the patient no. and no. of the week. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8): doi: /382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

7 Figure 1. Median virologic and immunologic data for the hepatitis C virus (HCV) increaser (black symbols) and HCV stable (white symbols) groups at weeks 0, 16, and 48. Squares, CD4 cell count; diamonds, log<sub>10</sub> HIV load; and triangles, log<sub>10</sub> HCV load. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8): doi: /382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

Download ppt "Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects."

Similar presentations

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.
Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced
Treatment-Naïve Adults

Treatment-Naïve Adults
Figure 3 Escape into the cytosol and subsequent intracellular replication during an infection of J774 macrophages with Listeria monocytogenes ΔactA (diamonds),

Figure 3 Escape into the cytosol and subsequent intracellular replication during an infection of J774 macrophages with Listeria monocytogenes ΔactA (diamonds),
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.

Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
International Journal of Infectious Diseases

International Journal of Infectious Diseases
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
ARV-trial.com Switch to ATV/r + 3TC ATLAS-M Study.

ARV-trial.com Switch to ATV/r + 3TC ATLAS-M Study.
Table 1. Prevalence of hepatitis B surface antigen (HBsAg) in west African cohorts from different countries. From: Low Genetic Diversity despite Hyperendemicity.

Table 1. Prevalence of hepatitis B surface antigen (HBsAg) in west African cohorts from different countries. From: Low Genetic Diversity despite Hyperendemicity.
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.
Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5
Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, 2013. From: Evaluation.

Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, From: Evaluation.
From: Postinfectious Irritable Bowel Syndrome

From: Postinfectious Irritable Bowel Syndrome
From: Treatment of Refractory Whipple Disease with Interferon-γ

From: Treatment of Refractory Whipple Disease with Interferon-γ

Similar presentations

Ads by Google